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E-mail address: twigle@epizyme.com (T.J. Wigle).Heterozygous point mutations at Y641 and A677 in the EZH2 SET domain are prevalent in about 10–
24% of Non-Hodgkin lymphomas (NHL). Previous studies indicate that these are gain-of-function
mutations leading to the hypertrimethylation of H3K27. These EZH2 mutations may drive the pro-
liferation of lymphoma and make EZH2 a molecular target for patients harboring these mutations.
Here, another EZH2 SET domain point mutation, A687V, occurring in about 1–2% of lymphoma
patients, is also shown to be a gain-of-function mutation that greatly enhances its ability to perform
dimethylation relative to wild-type EZH2 and is equally proﬁcient at catalyzing trimethylation. We
propose that A687V EZH2 also leads to hypertrimethylation of H3K27 and may thus be a driver
mutation in NHL.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The EZH2 gene encodes a SET domain-containing lysine methyl-
transferase that forms a complex with 3 to 4 other partners (Suz12,
EED, RbAp48 and AEPB2) known as the Polycomb Repressive Com-
plex 2 (PRC2). PRC2 methylates lysine 27 on histone H3 (H3K27)
up to three times; trimethylated H3K27 represses the transcription
of proximal genes [1], playing an important role in X-inactivation,
stem cell pluripotency and germline development [2]. Many stud-
ies have implicated EZH2 overexpression in the development,
aggressiveness and metastatic potential of an array of solid tumors
[3–7] and hematopoietic malignancies [8,9]. Additionally, loss-of-
function mutations in UTX, an H3K27 demethylase, are frequently
seen in a number of cancers [10–12], emphasizing the importance
of the methylation status of H3K27 in oncogenesis.
Several whole-genome sequencing efforts of cell lines and pri-
mary tumor samples have identiﬁed genes involved in chromatin
and transcriptional regulation that are commonly mutated inchemical Societies. Published by E
a; CPM, counts per minute;
lysine 27; NHL, non-Hogdkin
PRC2, Polycomb Repressive
nosylhomocysteine; 3H-SAM,Non-Hodgkin Lymphomas (NHL). These include EZH2,MLL2,MEF2B
and CREBBP among others [13–17]. Of particular interest, EZH2
mutations occur in a unique and mechanistically clear pattern;
roughly 10–24% of Non-Hodgkin lymphoma patients are heterozy-
gous for point mutations at two speciﬁc residues, Y641 and A677,
in the catalytic SET domain of EZH2. Additionally, cells and tumor
tissue harboring these heterozygous mutations display a clear
reduction in dimethylated H3K27, but have elevated trimethylated
H3K27. Biochemical studies using recombinant enzymes containing
all of these mutations (Y641F, Y641N, Y641H, Y641S, Y641C and
A677G) have revealed stark changes in enzymatic function
[17–20]. In the case of the Y641 mutants, the substrate speciﬁcity
is reversed from the wild-type enzyme such that the catalytic
efﬁciency isweakest for the unmethylatedH3K27 state but gets pro-
gressively greater with increasing methylation status [18–20],
while the A677G mutation enhances EZH2 activity on substrates
of all H3K27methylation states [17]. It is hypothesized that in lym-
phomas with heterozygous EZH2 mutations, the pairing of wild-
type and gain-of-function EZH2 mutants creates an accelerated
pathway towards trimethylated H3K27, thus promoting the malig-
nant transformation of B-cells [17,18].
Due to the important status of EZH2 and dysregulation of H3K27
trimethylation in cancer research, we were inspired to examine
additional mutations in the EZH2 SET domain. Themutational anal-
ysis of EZH2 from two massive whole genome sequencing efforts
[15,16] of Non-Hodgkin lymphoma were analyzed, and the A687Vlsevier B.V. All rights reserved.
Fig. 1. An EZH2 SET domain model showing the location of the several mutation
sites discussed in the text. The model and the location of SAH are based on the
crystal structure of the MLL1 SET domain (PDB code 2W5Z). The Ca trace of the
EZH2 SET domain is presented and the side chains of A687, Y641 and A677 are
colored in magenta, while the residues forming the hydrophobic core with A687 are
colored in green.
Fig. 2. Steady-state kinetics of peptide substrate utilization by recombinant PRC2
complex containing A687V EZH2. The peptide substrates used here all represented
histone H3, residues 21–44, with lysine 27 present in the zero-, mono- or
dimethylated state. The mean and standard error of 3 experiments is plotted.
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function. To investigate the biochemical effect of this point muta-
tion within proximity to the Y641 and A677 residues, we puriﬁed
PRC2 containing A687V EZH2 and characterized its ability to meth-
ylate histone H3 peptides with zero-, mono- or dimethyl lysine 27.
Our ﬁndings indicate that, indeed, A687V is another example of a
gain-of-function EZH2 mutation that widens the scope and impor-
tance of EZH2 alterations in Non-Hodgkin lymphomas.
2. Materials and methods
Recombinant 4-component PCR2 was produced in Spodoptera
frugiperda (Sf9) cells using a baculovirus expression system. Wild-
type EZH2 (NM_004456) was coexpressed with wild-type FLAG-
EED (NM_003797), SUZ12 (NM_015355), and RbAp48 (NM_005610).
An N-terminal FLAG tag on the EED was used to purify active PRC2
complex from cell lysates. For production of mutant 4-component
PCR2, EZH2 carrying the A687V mutation was co-expressed with
wild-type FLAG-tagged EED (NM_003797), SUZ12 (NM_015355) and
RbAp48 (NM_005610), again using the baculovirus system. The
FLAG-tag was used for puriﬁcation. The purity and stoichiometry of
the subunits of theﬁnal PRC2preparationswasassessedbySDS–PAGE
with Coomassie blue staining andmicroﬂuidic capillary electrophore-
sis (Agilent Bioanalyzer). Peptide substrates representative of histone
H3residues21–44containingeitherzero-,mono-,di-or trimethylated
lysine 27 and a C-terminal biotin (appended to a C-terminal amide-
capped lysine) were HPLC-puriﬁed to greater than 95% purity. The
enzyme assay was performed with 4 nM wild-type enzyme or 2 nM
A687V enzyme as previously described [18,19] using 0.8 lM unla-
beled SAM and 0.2 lM 3H-SAM and a peptide titration.
3. Results
Recent whole-genome sequencing efforts in B-cell lymphoma
were analyzed for the mutation status of EZH2. A study by Morin
et al. comparing normal samples to malignant samples that in-
cluded 13 diffuse large B-cell lymphomas, 1 follicular lymphoma
and 113 other non-Hodgkin lymphomas identiﬁed 109 mutated
genes. Out of 127 total cases, EZH2 was mutated at Y641 (Y641F,
N, S, H) 31 times (24.4% frequency), and was found to also have
one A677G (0.8% frequency) and one A687V (0.8% frequency)
mutation [15]. Each of these EZH2 point mutations was conﬁrmed
to be heterozygous. In another study, whole-genome exome
sequencing of diffuse large B-cell lymphoma was performed by
Lohr et al., and revealed that 5/49 patients (10.2% frequency) car-
ried a Y641 mutation (Y641F or N) and 1/49 (2% frequency) had
the A687V mutation [16]. In the Morin et al. study, the subtype
classiﬁcation of the lymphoma is not available, however in the
Lohr et al. study, the lymphoma with the A687V mutation is clas-
siﬁed as diffuse large B-cell lymphoma.
A 3-dimensional model of the EZH2 SET domain was con-
structed based on the crystal structure of the MLL1 SET domain
(PDB code: 2W5Z) using SWISS-MODEL [21] to visualize the loca-
tion of the A687V mutation relative to the known gain-of-function
mutations at Y641 and A677 (Fig. 1). In this model, the A687 resi-
due is located near a bound molecule of the product SAH. The side
chain of the A687 residue is forming a hydrophobic core with res-
idues I631, I689, I715 and F729 in proximity to the Y641 residue
and may be part of the putative lysine binding channel. The side
chain of the Y641 residue is pointing towards the lysine binding
channel and the A677 residue is situated behind this putative
channel. From this observation it could be rationalized that an
A687V substitution could potentially alter the substrate speciﬁcity
or catalytic efﬁciency of EZH2 based on the methylation state of
H3K27. To test this hypothesis, A687V EZH2 was cloned and therecombinant 4-component PRC2 complex (EZH2 A687V, Suz12,
RbAp48 and FLAG-EED) was expressed with and puriﬁed by the
FLAG afﬁnity tag, analogous to the wild-type enzyme puriﬁcation
[19]. The PRC2 complex was judged to be 93% pure, having near
1:1 stoichiometry between all the subunits. The activity of this
complex was initially interrogated in parallel with the wild-type
enzyme by examining the ability to transfer tritiated methyl
groups from 3H-SAM to a series of biotinylated peptides spanning
residues 21–44 of histone H3 and representing all states of H3K27
methylation (0, 1, 2 and 3). A full kinetic analysis was performed
on the A687V EZH2-containing PRC2 complex as illustrated in
Fig. 2 and compared to data previously obtained for the wild-type
enzyme [19]. The peptide substrates containing zero-, mono- and
dimethyl lysine 27 were titrated and K1/2 and kcat values were
determined; these data are tabulated in Table 1. The peptides dis-
played sigmoidal behavior and the data were ﬁt using a sigmoidal
Table 1
Steady-state kinetic parameters for methylation reactions catalyzed by PRC2




K1/2 (nM) kcat (h1) kcat/K1/2
(h1 nM1  104)
Wild-typea 0 157 ± 12 4.80 ± 0.20 305 ± 26
1 337 ± 26 3.33 ± 0.21 99 ± 9
2 144 ± 11 1.08 ± 0.04 75 ± 6
A687 V 0 118 ± 3 0.21 ± 0.04 17 ± 25
1 284 ± 10 11.40 ± 3.22 401 ± 92
2 331 ± 38 3.07 ± 0.80 93 ± 6
a Historical data for the wild-type enzyme was used to make the comparison
with the A687V mutant [19].
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mine the concentration of peptide resulting in half-maximal veloc-
ity [18,22]. In addition, the catalytic efﬁciency of the mutant and
wild-type enzymes is compared by analysis of the ratio of kcat/K1/
2 for each peptide substrate. The enzymes showed no activity on
a peptide of the same length and sequence containing trimethylat-
ed lysine 27 (data not shown), ensuring that there was no methyl-
ation at a lysine other than H3K27 occurring.
4 Discussion
Mutational analysis of EZH2 in Non-Hodgkin lymphomas,
culled from two separate large sequencing efforts, revealed that
between 10 and 24% of these cases were characterized as having
EZH2 SET domain mutations at Y641 (Y641F, N, H and S). Another
mutation at A677G was found to occur in about 1% of the cases.
These mutations have been well-characterized in both cell-based
and enzymatic assays to change the substrate speciﬁcity of EZH2
such that, when paired with a wild-type enzyme, they lead to
hypertrimethylation of H3K27, and implicate this mutation as a
driver of lymphomagenesis [17,18,20]. Also of interest, is another
potential heterozygous SET domain mutation of EZH2 at A687V
that is observed in about 1–2% of patients. Using recombinant
PRC2 containing A687V EZH2 and a series of peptides representing
different methylation states of lysine 27, we found this mutation to
alter the activity of EZH2 with respect to the methylation status of
lysine 27 of histone H3. While this is akin to the effect seen with
the Y641 and A677 mutations, the pattern of substrate usage by
the A687V mutation is unique. In Fig. 3, the K1/2, kcat and catalytic
efﬁciency, measured as kcat/K1/2, are plotted with respect to pep-
tides with zero-, mono- and dimethyl lysine 27 for both A687V
and wild-type EZH2. Inspection of the K1/2 plots reveals that the
A687 mutation causes a modest decrease in ground-state substrate
recognition as the methylation state increases to mono- or di-
methyl lysine 27. However, what is striking is the nearly three-foldFig. 3. Steady-state kinetic parameters for recombinant PRC2 containing WT or A687V E
states of H3K27 inﬂuences the (A) K1/2, (B) kcat and (C) kcat/K1/2 ratio. The mean and staincrease in transition-state recognition with respect to the
H3K27me1 and H3K27me2 peptides, observed by inspection of kcat
plots. Overall, in comparison to the wild-type enzyme, the catalytic
efﬁciency of the A687V EZH2 is drastically reduced on the
H3K27me0 peptide, but is greatly enhanced on the H3K27me1
peptide, and is virtually the same on the H3K27me2 peptide. This
is in contrast to the Y641 mutations that see their catalytic efﬁ-
ciency increase with increasing methylation state [17–19] or the
A677G mutation which is catalytically proﬁcient on all H3K27 sub-
strates [17].
Relating these mutations to the overall architecture of the SET
domain, modeled in Fig. 1, we see that the A687 residue could be
part of the putative lysine binding channel and hydrophobic core
located near the Y641 residue. The A677 residue, in contrast, is be-
hind the Y641 residue. Mutation of the A687 residue to valine
could alter the size of the lysine binding channel directly or enlarge
the hydrophobic core in turn to shift the location of the Y641 res-
idue. It is hypothesized that the Y641 residue and analogous resi-
dues in other PKMTs are steric gatekeepers that restrict the
ability to perform trimethylation [17–19,23,24]. It is believed that
mutation of Y641 to another residue changes the orientation of the
Y641 residue further away from the lysine binding pocket
[17,18,23]. This change presumably causes the lysine binding
channel to become more permissive to substrate lysines bearing
H3K27me2, but disrupts the ability to interact with the unmethy-
lated lysine due to loss of hydrogen bond between the tyrosine hy-
droxyl and the amino group of lysine. In the same vein, it is
predicted that the A677G mutation also encourages the Y641 res-
idue to adopt a similar conformation, but leaves the hydrogen-
bonding ability intact, creating a mutant enzyme that is proﬁcient
on all methylation states [17]. We propose that the A687V muta-
tion may be acting by either mechanism: 1) the additional two
hydrophobic methyl groups of valine directly affect the steric
interactions with H3K27, or 2) the additional two hydrophobic
methyl groups indirectly affect the lysine binding site by causing
the Y641 residue to adopt a conformation that increases the phys-
ical space within the lysine binding channel. However in the ab-
sence of an X-ray crystral structure for EZH2, we are unable to
make a deﬁnitive conclusion as to which, if either, of these two
mechanisms may be utilized. While the A687V mutation greatly
enhances the utilization of monomethylated substrate, we propose
that it does not alleviate the steric crowding sufﬁciently to cause
an improvement in the use of the dimethylated substrate.
H3K27 methylation is an important epigenetic mark that is al-
tered in many solid and hematologic cancers [3–9]. This mark is
methylated by PRC2 complexes containing either EZH1 or EZH2
and it is demethylated by the enzymesUTX and JMJD3. Among these
enzymes, several studies have shown consistently and unambigu-
ously that EZH2 knockdown attenuates both hypertrimethylationZH2 as functions of H3K27 methylation state, illustrating how different methylation
ndard error of 3 experiments is plotted.
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cer cells.
Recent studies in lymphoma have shown that mutations of spe-
ciﬁc residues in the EZH2 SET domain, at Y641 and A677, alter the
substrate utilization of the enzyme in such a way that, in concert
with the wild-type enzyme, leads to hypertrimethylation of
H3K27 and resultant lymphomagenesis. In the present study we
have shown that the A687V mutation in EZH2 also alters the pat-
tern of substrate utilization, in this case greatly favoring methyla-
tion of the H3K27me1 state over other H3K27 forms. This
observation leaves open the question of whether cells containing
the A687V mutation would display hypertrimethylation of
H3K27, as a result of enzymatic coupling with wild-type EZH2
activity. The current lack of cultured cell lines containing this
mutation has precluded our ability to experimentally address this
important question. However, this inference seems reasonable in
that the altered activity of the A687V mutant would be expected
to result in a disproportionate build-up of the H3K27me2 state,
the substrate for enzymes performing the H3K27me2 to
H3K27me3 reaction (i.e., both wild-type and A687V mutant
EZH2). Hence, based simply on Michaelis–Menten kinetics one
would expect the ﬂux through the H3K27me0 to 1 to 2 to 3 system
to increase in A687V mutant-bearing cells, resulting in elevated
levels of the lymphomagenetic H3K27me3 state. Thus, the A687V
EZH2 mutant deserves further in vitro and in vivo study, as it is
likely to be an addition to the known repertoire of EZH2 genetic
alterations that lead to tumorigenesis in human cancers.
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